Dose-Dense Chemo Regimen Could Benefit Some Ovarian Cancer Patients

by: cancercompass

New research suggests that dose-dense chemotherapy improves survival in women with advanced ovarian cancer, reports U.S. News & World Report.

A common first-line treatment for patients with advanced epithelial ovarian cancer is paclitaxel and carboplatin every three weeks. Research from Japan, however, suggests dose-dense weekly treatment with paclitaxel may increase overall survival in these patients.

During this phase 3 study, researchers analyzed 637 women by comparing the two treatment methods. All participants had advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

According to the report, of the 637 women, 320 received conventional treatment of six cycles of paclitaxel and 317 received the dose-dense paclitaxel on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

Researchers found women in the dose dense group had a 29% lower risk of cancer progression and a 25% lower risk of death than women in the conventional treatment group.

Toxicity caused 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment. Severe anemia was experienced by 214 patients (69%) in the dose-sense group and in 137 (44%) of the standard therapy group.

The study was published recently in The Lancet.

What are your thoughts about this new chemotherapy treatment? Share your experiences with treatments that fight gynecological cancers by posting your thoughts at the CancerCompass Gynecological Cancer Message Board.